Intracellular accumulation of amyloid-ß is a marker of selective neuronal vulnerability in Alzheimer's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40467545.
- Also identified by DOI 10.1038/s41467-025-60328-w and PMC identifier 12137956.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Defining how amyloid-β and pTau together lead to neurodegeneration is fundamental to understanding Alzheimer's disease (AD). We used imaging mass cytometry to identify neocortical neuronal subtypes lost with AD in post-mortem brain middle temporal gyri from non-diseased and AD donors. Here we showed that L5,6 RORB<sup>+</sup>FOXP2<sup>+</sup> and L3,5,6 GAD1<sup>+</sup>FOXP2<sup>+</sup> neurons, which accumulate amyloid-β intracellularly from early Braak stages, are selectively vulnerable to degeneration in AD, while L3 RORB<sup>+</sup>GPC5<sup>+</sup> neurons, which accumulate pTau but not amyloid-β, are not lost even at late Braak stages. We discovered spatial associations between activated microglia and these vulnerable neurons and found that vulnerable RORB<sup>+</sup>FOXP2<sup>+</sup> neuronal transcriptomes are enriched selectively for pathways involved in inflammation and glycosylation and, with progression to AD, also protein degradation. Our results suggest that the accumulation of intraneuronal amyloid-β, which is associated with glial inflammatory pathology, may contribute to the initiation of degeneration of these vulnerable neurons.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Neurons